GlassScriptPhysician profile
Duane C Berkompas
NPI 1174521116
$158,846.85
in general payments reported to CMS, 2019-2025
19 companies · $29K in 2025
The $29K reported for 2025 was more than what 95% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,678 · 2020: $5,538 · 2021: $6,240 · 2022: $18K · 2023: $57K · 2024: $39K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Travel and Lodging: $15K · Consulting Fee: $9,125 · Food and Beverage: $6,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,218.75 |
| Travel and Lodging | $15,248.31 |
| Consulting Fee | $9,125.00 |
| Food and Beverage | $6,862.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $120,294.02 | 2021-2025 | Corevalve Evolut R, Symplicity G3 |
| Abbott Laboratories | $23,874.10 | 2019-2025 | Amplatzer Amulet, Mitraclip, Navitor |
| Medtronic Vascular, INC. | $5,986.34 | 2019-2020 | |
| Boston Scientific Corporation | $2,444.76 | 2019-2024 | Watchman |
| Edwards Lifesciences Corporation | $2,436.42 | 2021-2024 | Evoque, Pascal, Konect Resilia |
| W. L. Gore & Associates, INC. | $1,862.06 | 2019 | |
| Ancora Heart, INC. | $1,151.00 | 2021 | |
| Abiomed | $286.24 | 2022-2025 | Impella |
| Shockwave Medical, INC | $159.54 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Livanova USA, INC. | $78.79 | 2023 | Tandemheart |
| Novartis Pharmaceuticals Corporation | $57.20 | 2025 | |
| Baxter Healthcare | $55.78 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Heartflow, INC. | $43.30 | 2022 | |
| Philips North America LLC | $40.44 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.15 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $19.10 | 2025 | Supercross |
| Acist Medical Systems, INC. | $16.61 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$325,302.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Berkompas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.